Navigation Links
FDA Approves Longer Duration Efficacy and Safety for EUFLEXXA®
Date:10/21/2011

PARSIPPANY, N.J., Oct. 21, 2011 /PRNewswire/ -- On Oct. 11, 2011, the FDA approved a labeling supplement for EUFLEXXA (1% sodium hyaluronate) that provides 26-week efficacy data from the FLEXX trial, as well as, 52-week safety data to demonstrate the safety of repeated injection cycles.

The FLEXX trial was a 26-week multicenter, randomized, double-blind study evaluating the safety and efficacy of EUFLEXXA, compared with saline, in patients with painful osteoarthritis of the knee. Patients received three weekly injections of either EUFLEXXA or saline into the target knee. Following the double-blind portion of the trial, patients were offered to receive an additional three weekly injections of EUFLEXXA in a 26-week open-label safety extension. Results from the double-blind portion of the study showed patients treated with EUFLEXXA had a statistically and clinically significant decrease in osteoarthritis knee pain compared to those who received saline control injections as measured by a 50-foot walk test at week 26.

The number of patients reporting adverse events was generally similar between the EUFLEXXA and saline groups. The most common adverse events (>2%) reported in patients treated with EUFLEXXA were: arthralgia, hypertension, back pain, upper respiratory tract infection, diarrhea, injury and cough. In addition, results of the open-label extension demonstrated that repeated injection cycles of EUFLEXXA were well-tolerated up to 52 weeks. In this open-label portion of the study, the most commonly reported adverse events (>2%) were: arthralgia, nasopharyngitis, injury, back pain, joint swelling, upper respiratory tract infection and sinusitis.

"The results further support EUFLEXXA as the first bioengineered, non-avian, effective treatment option that provides osteoarthritis knee pain relief lasting up to six months. The labeling also reflects safety with repeated injection cycles," said Dr. Paul Korner, Senior Vice President,
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ... insulin delivery systems especially for type 1 ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ... fat content and preserved lean body mass following ...
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 ... , offers Los Angeles a premier ... Duality laser and a $99 treatment special. Dr. Brandeis, focus ... medical technology and offering expert medical advice to all patients. ... a dramatic increase in the presence of tattoo regret and ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , , MUMBAI, India , ... Organization (CRO) with a presence in India , Western ... today announced its alliance with DreamCIS Inc., a leading CRO ... has nearly a decade of experience in offering clinical research ...
... , CRANBURY, N.J. , Feb. 9 ... the completion of first cohort dosing in a placebo-controlled, multiple ...  The primary endpoint in this double-blind safety study is evaluation ... 45 and 65 years old.  The study will also evaluate ...
Cached Medicine Technology:SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 2SIRO Clinpharm Forms Alliance with Korean CRO DreamCIS 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Guaranteed Healthcare, AFL-CIO Secretary Treasurer Richard Trumka to Keynote ... ... Patients, First Responders to Join Emotional September 11th Rally With ... Californians, OAKLAND, Calif., Sept. 6 The California Nurses,Association/National ...
... to Support EIF,s Women,s ... Cancer Research Fund, ... edition version of its all-new, eagerly-awaited 2008,C350 Sport Sedan to raise ... initiative developed in partnership with the Entertainment,Industry Foundation,s (EIF) Women,s Cancer ...
... will participate in a nationwide study to pinpoint the ... infection. , The objective of this trial is ... people who have MRSA, said David Karras, professor and ... Medicine and Hospital, who will lead the research efforts ...
... Tim McGraw and Friends, ... Presented by Anheuser-Busch Companies, NAPA, Calif., Sept. 6 ... on Friday, Nov. 2 at Grant,s Farm,the ancestral home of ... "Denim & Diamonds: An Evening with Tim McGraw and,Friends". Proceeds ...
... Predictive medicine company,PreMD Inc. (TSX: PMD; Amex: PME) ... U.S. Food and Drug Administration (FDA) regarding its,510(k) ... POC skin,cholesterol test. PreMD submitted the 510(k) application ... to obtain broader clearance in the assessment of,cardiovascular ...
... may open a window of vulnerability for developing binge ... according to a study from the University of North ... , In a long-term study of 100,000 pregnant Norwegian ... incidences of binge eating disorder that began during pregnancy. ...
Cached Medicine News:Health News:Hundreds of RNs from Across U.S. and World to Join California Nurses Association/NNOC National Convention 2Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 2Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 3Health News:Mercedes-Benz Special Edition C350 Sport Sedan to Raise $1 Million for Saks Fifth Avenue's KEY TO THE CURE 4Health News:Temple Emergency Medicine receives $1.8M to find best MRSA treatment 2Health News:Temple Emergency Medicine receives $1.8M to find best MRSA treatment 3Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 2Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 3Health News:The Tug McGraw Foundation Announces 2007 Fundraising Gala 4Health News:PreMD Provides Update on 510(k) Application for PREVU(x) POC 2Health News:Pregnancy may increase the risk of developing binge eating disorder 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: